Stem cells and PRP for fertility: what is real, what is early, what to ask.

Most people do not start with a stem cell question. They start with a low AMH result, a failed IVF cycle, an age deadline, or a clinic that just used the phrase “ovarian rejuvenation.” PRP, stem cells, MSCs, and exosomes sit in the hopeful middle: plausible biology, early human signals, and marketing that often runs faster than the evidence.¹

For many readers, the search began long before the search bar. A cycle that did not work. An embryo that did not implant. A pregnancy that ended too soon. A number on a chart that was not the one you hoped for. Underneath those facts is something this page wants to acknowledge before it tries to be useful: wanting a child, sometimes after years of trying, sometimes after loss. The biology is interesting and worth following honestly. So is the patience required to read it clearly.

The useful question is not can this make me fertile again? It is: what outcome is being measured, in which patient group, with which product, by which route, under whose oversight? That is the page. It is not a prescription, not a promise, and not a warning to put the research down — it is the shape of what is known so far, in plain English.

If you are reading this after a hard cycle or a hard conversation, take your time with it. The work below is meant to help you ask sharper questions of a reproductive endocrinologist who knows your case, not to replace that conversation.

What patients are really hoping for.

“Will this help my fertility?” is a humane question and a hard one to answer cleanly, because the hopes folded into it are not the same endpoint. A study that moves one of these can be honestly described as helpful and still leave the others untouched. Separating them is most of the work.

• More follicles

  A higher resting follicle count visible on an early-cycle ultrasound — a measurement, not a baby.

• Better ovarian response

  More eggs growing under stimulation in a given IVF cycle than the last cycle produced.

• Better egg quality

  Eggs that fertilize, develop, and survive to embryo — a downstream outcome, not visible on ultrasound.

• Lower IVF medication burden

  Reaching the same number of eggs with fewer injections, lower doses, or shorter stimulation.

• Pregnancy

  A positive test and an ultrasound that confirms a clinical pregnancy. Not the same as a baby home.

• Live birth

  The outcome that actually matters at the end of the road. The hardest one to demonstrate in a study.

• Delaying menopause or hormone change

  A separate claim from fertility, with its own evidence and its own meaning. Often conflated; should not be.

None of these is a worse hope than any other. They are different things, and clinic marketing tends to talk about one while citing evidence for another. The rest of this page tries not to do that.

Ovarian response vs pregnancy vs live birth.

Most marketing claims for fertility-related regenerative procedures cite something that changed after treatment. What changed matters. A clinic can honestly report that AMH rose, or that more follicles appeared in the next ultrasound, and still not have shown what a patient cares about, which is usually a baby. The ladder below names the rungs in order.²

1. 01

   AMH and AFC (reserve markers)

   Measures How much ovarian reserve there is on a given day — a blood marker (AMH) and an early-cycle ultrasound count (AFC).

   Does not settle Whether a cycle will produce more eggs, whether eggs will fertilize, or whether a pregnancy will follow.

2. 02

   Ovarian response to stimulation

   Measures How many follicles grow when stimulation medication is given. A within-cycle behaviour.

   Does not settle How many of those follicles contain a mature egg, or how those eggs perform after retrieval.

3. 03

   Eggs retrieved

   Measures The actual count of eggs collected at retrieval — a clinic number, by the end of a single cycle.

   Does not settle Egg quality. A higher count does not, by itself, mean a higher chance of a usable embryo.

4. 04

   Embryos created (and usable embryos)

   Measures How many eggs fertilized, how many developed to blastocyst, and how many are usable on day 5 or 6.

   Does not settle Whether an embryo transfer will result in a clinical pregnancy. Embryos can be normal and still not implant.

5. 05

   Clinical pregnancy

   Measures A positive beta-hCG followed by an ultrasound confirming a gestational sac or fetal heartbeat.

   Does not settle Whether the pregnancy reaches live birth. Some clinical pregnancies end in miscarriage.

6. 06

   Live birth

   Measures A baby born. The endpoint closest to what patients actually came for, and the one that takes the longest to demonstrate.

   Does not settle This is the rung studies aim at; a result here still needs to be read with the safety profile, the patient group, and how the outcome was measured.

A study can move rung one and stop there. That is not deception on its face — it is what the study did. The mismatch shows up when a marker change is described, in a brochure, as if it were a baby. When you read a fertility claim, the most useful question is: which rung is this evidence on?

What treatments are usually being discussed.

Six things tend to live under the fertility-and-regenerative umbrella. They are not the same product, the same procedure, or the same regulatory category. For each: what it is, what patients hope it might do, what is still uncertain, and one plain question to bring to the consult.

For the longer field guide on what is actually in the syringe across the wider regenerative-medicine market, see stem cells vs PRP vs exosomes vs BMAC.

What the human evidence can and cannot say yet.

The fertility literature on PRP and cell-based ovarian procedures is real, growing, and uneven. A patient who reads it honestly will find a few patterns worth keeping in mind, rather than a single number that settles things.³

• Most published work is small. Case series and single-arm pilot studies dominate. Larger randomized trials with sham or active comparators are fewer, more recent, and not all positive.
• Patient selection differs. Diminished ovarian reserve, poor ovarian response, premature ovarian insufficiency, and perimenopause are different starting points. A signal in one group does not automatically transfer to another.
• Reserve markers are not live birth. AMH and antral follicle counts can shift inside the normal noise of cycle-to-cycle variation, and reserve markers correlate imperfectly with the outcomes patients actually want.
• Placebo and comparison matter. Patients who pay out of pocket tend to report improvement, and ovarian response varies cycle to cycle without intervention. A real effect has to clear that noise.
• Fertility outcomes take time to measure. A live-birth endpoint is, at minimum, a nine-month clock after a successful transfer — and that is after enrollment, treatment, stimulation, retrieval, embryo development, and implantation. Definitive answers are slow on purpose.
• The field is interesting because the biology is. Researchers are studying these protocols because the underlying questions about follicle reactivation and ovarian signaling are worth studying. That is a real reason to follow the science. It is not a reason to convert early findings into a treatment narrative.

None of the above means the field is silly. Follicle reactivation and ovarian signaling are real phenomena in real cells, and they are being studied because the underlying biology earns the attention. The hopeful part is real. The hard part is showing which patients, with which exact product, on which outcome — and that is the work this page is trying to make readable.

For the broader site framing on how we read evidence at different rungs of the ladder, see how to read stem cell evidence without getting lost.

What researchers are studying around the world.

This is not a study dump. The shape of the global literature, at a high altitude, is more useful than any single citation. Five patterns — what is being studied, where the work clusters, and where the evidence is strongest and weakest.³

• Intraovarian PRP for diminished reserve and poor response. The most active strand of human research in this area, with case series and small pilot studies published from reproductive-medicine groups across Europe, the Middle East, South Asia, the United States, and elsewhere. The endpoints most often reported are AMH and antral follicle count over a short window. Fewer studies report eggs retrieved or embryo development. Fewer still report pregnancy. Few report live birth.
• “Ovarian rejuvenation” PRP. The same procedure family under a more marketing-heavy banner. Same shape of evidence: marker changes are easier to report than birth outcomes. Both ClinicalTrials.gov and the WHO ICTRP list registered studies under one phrasing or the other.
• MSC and cell-based ovarian work. A smaller body of human research using bone-marrow-derived or umbilical-cord-derived cells, most often in premature ovarian insufficiency or repeated poor response. Protocols, cell sources, and delivery routes vary widely between groups, which makes cross-study comparison hard. Registered trials appear in several national registries.
• Exosome and secretome work. Largely preclinical — cell and animal models. Human reproductive applications are very early, with limited and inconsistent registry presence. No exosome product is approved by the U.S. FDA for fertility, and the agency has issued specific safety communications about unapproved exosome marketing. Outside the U.S., authorization status is product-specific and country-specific.
• What none of the above settles yet. Across the full body of research, the strongest signals are at the marker level — AMH, antral follicles, sometimes eggs retrieved. Live birth is the weakest-evidenced endpoint, partly because it takes the longest to measure and partly because comparison groups are hard to assemble at the population sizes a confident answer requires.

A second thing worth saying out loud: available abroadis not one thing. When a clinic says a procedure is “offered in” a country, that can mean a registered clinical trial with ethics-committee oversight; a hospital-level protocol or exemption for a defined indication inside a licensed institution; a national-regulator authorization, full or conditional, for a specific named product; or a private clinic offering with none of the above attached. All four exist in the market. They should not be treated as equivalent — a registered trial with ethics oversight is a different kind of thing from a private clinic offering with no regulator, hospital pathway, or trial behind it. None of the four, on its own, is proof that the intervention works for a specific person; a private cash-pay offering with no named oversight is only a claim in the market, not evidence.

For the registries and regulators CellDecide reads alongside each other — ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform, the EU Clinical Trials Register, the Japan Registry of Clinical Trials, the Chinese Clinical Trial Registry, the Thai FDA, and others — see sources. For the longer regulatory framing CellDecide applies on every page that names a specific intervention, see methodology.

Where this research actually lives.

A short, source-checked reading list — not a study dump and not a recommendation. Five strands of work, each named with the kind of source a careful reader can verify, and each honest about what was measured rather than what was hoped for.³

• Intraovarian PRP for diminished reserve and poor response. Researchers have mostly tested whether injecting platelet-rich plasma into the ovary changes ovarian-reserve markers or cycle response in patients with low AMH or a previous poor IVF cycle. Reports are usually small and lack a comparison group, so what gets measured is most often a shift in markers, sometimes a count of eggs retrieved, less often a pregnancy, and less often again a live birth. Useful signal-hunting, not proof of a live-birth outcome. The work appears in PubMed-indexed reproductive medicine journals such as Aging, Reproductive BioMedicine Online, and Journal of Clinical Medicine, with registrations on ClinicalTrials.gov and the WHO ICTRP — listed under both the clinical phrasing and the marketing phrasings (ovarian rejuvenation, PRP ovarian rejuvenation).
• Bone-marrow cell delivery near the ovary in poor responders. Researchers have tested mobilizing a patient’s own bone-marrow cells and delivering them near the ovary in women who have responded poorly to past IVF stimulation. This is experimental, the studies are small, and the protocol is not part of standard fertility care; it is a line of work worth watching, not a treatment to expect at a clinic. The literature appears in PubMed-indexed reproductive medicine journals such as Fertility and Sterility (technical detail: mobilization is typically with G-CSF, with delivery via ovarian-artery infusion).
• Cell-based work in premature ovarian insufficiency. Researchers have tested giving patients with premature ovarian insufficiency a dose of mesenchymal stromal cells — sometimes from bone marrow, sometimes from fat, sometimes from umbilical cord — and watched for hormone or follicle changes. Sources, doses, and delivery routes differ between groups, which makes the studies hard to compare; most are small and lack a comparison group, so the results describe a signal in a handful of patients rather than a treatment effect across many. Registered in ClinicalTrials.gov and the Chinese Clinical Trial Registry (ChiCTR).
• Exosomes and cell-secreted material for ovarian recovery. Researchers have tested whether sub-cellular signaling material — exosomes and related extracellular vesicles released by cells — can help restore ovarian function in models of chemotherapy-induced damage. Most of this work is still in cell-and-animal models; human fertility studies are very early. No exosome product is approved by the U.S. FDA for fertility, and equivalent product-level authorization has not been put in place by other major regulators for a fertility indication either. Source-tail: stem-cell journals such as Stem Cell Research & Therapy.
• Reviews trying to pool the early data. As the case-series and pilot literature grew, several PubMed-indexed systematic reviews and meta-analyses have tried to pool what is known about intraovarian PRP. The honest summary across that aggregate work, where one can be made: modest marker-level signals reported with low- certainty evidence. Live birth remains the under-powered endpoint and the one a careful reader should keep watching.

A registered trial is a study being run, not proof that it works. A published case series is data, not a treatment claim. A clinic marketing page citing one of the above is a fourth thing again. Keeping those three categories visibly separate is most of the editorial work on a fertility page. The biology here is worth watching; the proof has to be outcome-specific.

FDA, overseas clinics, and the global reality.

In the United States, most fertility-related PRP and stem cell offerings are not FDA-approved fertility treatments. Some are permitted under specific in-clinic processing rules; some are offered as cash-pay services outside any approved use; some are being studied inside registered trials. FDA non-approval, on its own, does not say the biology is worthless — but it does mean the U.S. agency has not licensed the product for the fertility use being marketed.⁴

Abroad, the same procedures appear under different combinations of the categories described in the section above — sometimes inside hospital pathways at tertiary medical centers with ministry oversight, sometimes inside registered clinical-study protocols, sometimes as cash-pay services in private clinics outside any specific authorization for the indication being treated. Availability is not the same as approval, and approval is not the same as proof.

The useful question, on either side of the border, is: who oversees this exact product, for this exact fertility use, in this exact setting? A clinic that can name the regulator, the pathway, and the protocol — and, when there is one, the trial registration; or, when it is not a trial, the named hospital review, ministry pathway, ethics-board approval, product authorization, or local-regulator pathway that does apply — is doing the work. A clinic that gestures at “legal here” or “cleared internationally” without naming what or who has not. For broader site framing on this distinction, see methodology and what to know before traveling.

The promises patients should be careful with.

None of what follows is a judgment of the reader. Hoping for a child after a hard year of trying, or after watching a window close, is the most reasonable thing in the world. The phrases below are not bad because hope is bad. They are bad because they are doing more work than the evidence supports, and they tend to appear in the same conversations that lead to five-figure deposits.

• “Reverses menopause.”
• “Restores fertility.”
• “Guarantees eggs” or guarantees a pregnancy.
• “Works at any age.”
• “A natural IVF alternative.”
• “No risk, because it is your own blood or cells.”

Any of these in a brochure or a sales call is a reason to slow down — not necessarily to walk away, but to ask for the exact product, the exact study, the exact patient group, and the exact outcome that was measured. The broader pattern catalog, with what to say in their place, lives at stem cell clinic red flags.

Before you pay: fertility-specific questions.

If you searched “ovarian rejuvenation near me,” treat that as the start of a screening process, not the end of one. The list below is ten questions to bring to a consult or a phone call, written so the answers belong in writing. A clinic doing this work carefully will have most of these documents ready and will not mind you taking the answers home before deciding.

1. 01

   What exact product is used — PRP, a same-day cell preparation, lab-expanded cells, an exosome product, or something else?

2. 02

   Are cells injected into the ovary, infused, or delivered by another route? Under what anesthesia, by whom?

3. 03

   What patient group was studied — diminished reserve, poor responders, premature ovarian insufficiency, perimenopause? Am I in that group?

4. 04

   What outcome improved in the cited study: AMH, follicles, eggs retrieved, embryos, clinical pregnancy, or live birth?

5. 05

   Was there a control or comparison group, or only treated patients?

6. 06

   How many patients in total, and over how many cycles?

7. 07

   Who performs the procedure, with what training, at what kind of institution?

8. 08

   What complications have been reported in the literature for this exact procedure, and how does the clinic track outcomes?

9. 09

   What is included in the quote — the procedure only, the IVF cycle, follow-up, repeat dosing, complication coverage?

10. 10

    How does this interact with my IVF timing, and who coordinates with my reproductive endocrinologist before and after?

The longer pre-consult list — product identity, condition fit, evidence, oversight, procedure and safety, follow-up, cost — is at questions to ask a stem cell clinic before you pay.

On ovarian rejuvenation costspecifically: there is no single number, because the same procedure can be quoted as PRP alone, PRP bundled inside an IVF cycle, a package with imaging and monitoring, repeat dosing, or care abroad with travel folded in. Ask for the line items, not the headline. CellDecide’s current cost surfaces — what you are really paying for and the total-landed-cost estimator — describe the structure of the bill rather than a fertility-specific quote. Use them to plan around the categories; then ask your clinic to fill in the fertility-specific numbers in writing.

Common questions.

Short answers to the questions readers most often arrive with. The longer answers live in the sections above.

Can stem cells help fertility?

The biology is being studied because it is interesting, and some early human work reports short-window changes in ovarian reserve markers after intraovarian PRP or related cell-based procedures. That is not the same as showing that the same product produces more pregnancies or more live births in a controlled comparison. The honest answer today is: early, mixed, and condition-specific — not proven, and not nothing.

What is ovarian rejuvenation?

Ovarian rejuvenation is a marketing umbrella over a few different procedures, most commonly intraovarian PRP, in which a patient's own blood is processed to a platelet-rich concentrate and injected into the ovary. Sometimes the term covers cell-based protocols instead. The phrase is broader than any single tested protocol, which is why it matters to ask exactly what would be injected, by what route, on what schedule.

Does PRP improve egg quality?

Egg quality is hard to measure directly. What studies usually report is something upstream — AMH, antral follicle count, eggs retrieved — or something downstream, like embryo development. Reports are mixed, often small, and frequently lack a comparison group. PRP may shift a marker in some patients; whether that translates into more usable embryos or more live births for someone in your situation is a much larger question, and not one a single small study can settle.

Can PRP or stem cells reverse menopause?

No published evidence supports reversing menopause with PRP, stem cells, or related products, and “reverses menopause” is a claim CellDecide treats as a marketing red flag rather than a clinical category. Menopause-adjacent hormone effects, fertility, and ovarian biology are related but separate questions, and a careful clinic does not conflate them.

Is ovarian rejuvenation offered outside the U.S.?

Yes, in several countries — through a mix of hospital-based protocols, registered clinical studies, and cash-pay clinic offerings. The same is true of the broader fertility cell-based research: intraovarian PRP, MSC infusions, and IVF add-on combinations appear in trial registries and clinic offerings in parts of Europe, Latin America, Asia, and the Middle East. Availability under local rules is real, but the local rules differ a lot. A hospital ethics committee, a national regulator's notification, a registered clinical trial, and a private clinic operating outside any of those are different things — and “available abroad” does not, on its own, mean proven for the specific fertility use being offered.

Where to go from here.

If you want to keep reading before your next consult, these pages go deeper on the product, the questions, the warning signs, the cost, and the framework behind every page on this site.

What is actually in the syringe — a product field guide →

Questions to ask a stem cell clinic before you pay →

Stem cell clinic red flags →

Stem cell therapy cost: what you are really paying for →

Total-landed-cost estimator →

How to read stem cell evidence without getting lost →

How CellDecide reads a paper and writes a page →

Sources →

Disclosures →